1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Bhumsuk Keam ,H Zhang,Martin Schüler ,Ignacio Matos ,Giuseppe Curigliano ,Sophie Leboulleux ,Yann Godbert ,Aaron S Mansfield ,Matthew H Taylor ,Douglas Adkins ,Marcia S Brose ,Debashis Sarker ,Mimi I Hu ,Lori J Wirth ,Christopher D Turner ,Viola W Zhu ,Christina S Baik ,Vivek Subbiah ,Gilberto Lopes ,Chang-Ping Lin

doi:10.1016/j.annonc.2020.08.1401

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Bhumsuk Keam , H Zhang + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1401

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 30	License type: elsevier-specific: oa user license

#Registrational Phase #Advanced Thyroid Cancer + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Full Text